Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What was that phrase that frog used earlier? Oh yes, "mindless ad naseum repetition". I couldn't have put it better myself.
OT I have responded privately to your a couple of times in the past. You clearly didn't take either message on board. Sorry.
OT Are you familiar with the phrase "once bitten twice shy"?
frog, as you (and others) are well aware, no TOS rule covers "disruption" - although you might say that TBD's posts would comfortably qualify under the "duplicate" category? But I digress. As you (and others) are also well aware, the rules are applied fairly in order to allow honest debate. What is restricted at the end of the day is up to IHUB to decide. We both know what game is being played here. Personally I would prefer honest debate. But hey, that's JMHO.
The OS and AS was well covered by I think bag8ger yesterday. The executive compensation is raised on a regular basis by me actually. No subjects are taboo, but there is a difference between honest debate and disruption.
The company has explained that they are NOT going to be having a RS. That is your second post on this subject today. I now suggest that you drop this subject because there seems to be little intent to engage in serious debate.
I know of one person who was not too smart and who tried to sneak back using the same IP address. They now pontificate on RB about how bad IHUB is...
Your posting limit is related to your membership type, not the "powers that be", and your opinions have been given free reign on this board - as they will as long as the posts are within the TOS.
Robert
"Prior to RETINOME(TM), no predictive genome-based test had been developed, described in the peer- reviewed literature or, most importantly, launched commercially."
History indeed...
OT I love being able to remove spam...
Ann, yes. As bag8ger says, refer to the earlier posts.
One of the listed companies is quite unlike the others. Can you tell which it is?
TBM, it looks like the share price is up actually. The compant recently re-stated that they were not going to have a reverse split and the reason why. Sorry.
frog, yes it does seem at first sight to be a limitation. The DNAP pigmentation patent application describes the issues with iris color determination, and "brown" does seem to have some unique wrinkles of its own. However, despite these, the following is stated in the application:
"Having identified several penetrant feature SNP combinations of variable iris color shade, the analysis was extended to more completely investigate the associations of their penetrant genetic features with specific eye colors. From a contingency analysis of haplotypes and multilocus genotypes versus iris colors (blue, green, hazel, brown and black), numerous significantly associated alleles and allele combinations were associated..."
They seem to have found the eye color genes, some of which are also good ancestry informative markers (the special significance of pigmentation genes) but it is a complex trait involving multiple genes. Given the qualifications that are in the press release, perhaps "brown" for non-caucasian remains an issue that will be addressed in a future version of the product; notwithstanding the fact that we know intuitively that a very high percentage of individuals of non-caucasian ancestry will have brown eyes.
There was another interesting tidbit in the press release:
"DNAPrint's success with this difficult trait has profound implications for its goal of developing a pipeline of small molecule drugs that target specific human subpopulations,"
Now here's the thing:
http://www.dnaprint.com/pr_retinome.html
DNAPrint to Present RETINOME Launch and Other Advancements at Upcoming Conferences
April 30, 2002
RETINOME(TM) is the world's first and only complex genomics classifier for the inference of human iris color from DNA, capable of iris color inference with greater than 99% accuracy and iris color shade with significantly greater than 99% accuracy.
DNAPrint intends to commercialize the test to the US forensics community by year's end, and to other forensics scientists throughout the world by the end of 2003.
http://biz.yahoo.com/prnews/040817/fltu014_1.html
DNAPrint Announces the Release of RETINOME(TM) for the Forensic Market: Eye Color Prediction From Crime Scene DNA!
Tuesday August 17, 2004
The most recent blind validation test for 65 individuals of predominant (>80%) European ancestry, between the ages of 10 and 60 years, showed greater than 97% accuracy...
We know what happened and why further work was required on the product. This is perhaps one reason why the company is reluctant to make any statement about development schedules or anticipated completion dates, but that is IMO a mistake.
For the avoidance of doubt, there are six reasons why a post may be removed:
Duplicate – an accidental duplicate post by a member
Personal Attack – when someone attacks a person, with name calling, or relating to the messenger and not the message.
Spam – a message that is being posted promoting other sites, stock-related or not, that has no use in the discussion (for example, if your board is about Ford Motors, a link promoting amazing returns running a home-based business is worthless to the discussion).
Vulgarity – cursing of any kind unacceptable on your board
Violation of Privacy – posting of any personal identifiable information (email, real name, phone, address, etc)
Threat – someone threatening another member in some fashion
If you don't want to observe the above terms can I suggest that you find another forum e.g. RB. We have had several excellent discussions recently, which is the point of IHUB.
Gandolf3, it's very simple. The renewal of the executive compensation packages comfortably qualifies as something that should have been included in the 10Q.
bag8ger, we are not actually sure to what extent they have "gambled" themselves because the details of the renewed executive comepnsation packages (such renewal occurred in May) are also not contained within the 10Q...
I think that the most telling part of the 10Q for me is the "Summary" section, which has not changed one iota from the last 10Q. Apart from noting the benefit to the eye color product from the Rick Sturm publication, and the additional ancestry sub-groups in ABD 2.5, there is also no tangible statement about progress of the other products. This seems to be the extent of the communication in relation to pharmacogenomics products:
"...we continued to evaluate and analyze our preliminary results and to extend those results to other patients' samples for Taxol, Statins, and Ace inhibitor work."
and:
"In order to advance our pharmacogenomic product, OvanomeTM, to commercialization, it is anticipated that development costs for this product will increase throughout 2004."
Increasingly the SEC returns seem to contain the bare minimum of information required for their purpose. There is no other disclosure of information of interest to shareholders other than that contained in the recent shareholder's letter (which actually didn't mention the pharmacogenomic products other than in terms of the broad strategy the company intends to adopt) - for the reasons given by Richard Gabriel in this letter. Specifically, the company will not announce publicly information about research and development that "we do not believe is ripe for release" in relation to shareholder enquiries. The result is that shareholders would seem to have no way to judge progress (or delay) of the development of products such as Ovanome and Statinome. All we can tell from the above is that work is ongoing and, for Ovanome, this work will continue throughout 2004. Given such lack of communication, and consequent lack of transparency, I do not personally see how shareholders (or potential shareholders) can take informed decisions about their investment.
Mike, you make a lot of good points here, and I am largely in agreement with you (especially re O'Brien and Kidd). With regard to disclosure of information, there are a number of instances of inconsistency. The fact that attendees of the shareholders meeting saw a PowerPoint presentation that is not also generally available to other shareholders who did not attend is a case in point. I think that there is perhaps too much sheltering behind Sarbanes-Oxley and not enough awareness of the intent of the Act.
Will we get the 10Q today...
bag8ger, a look at the DNAP Paclitaxel patent application will tell you all you want to know about how specific DNAP's approach is relative to the research presented. However, there are multiple "competitive" approaches so it is important to bring some of this research to fruition.
DNAP are not the only ones working on predicting Paclitaxel response:
http://www.oncolink.upenn.edu/conferences/article.cfm?c=3&s=26&ss=154&id=1066
Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer
Reviewer: S. Jack Wei, MD
Abramson Cancer Center of the University of Pennsylvania
Posting Date: June 5, 2004
Presenter: M. Yoshimoto
Presenter's Affiliation: Cancer Institute Hospital, Tokyo, Japan
Type of Session: Scientific
Background
Many breast cancer patients receive chemotherapy as part of their treatment program
A common chemotherapeutic agent used in breast cancer is paclitaxel
Response to paclitaxel varies greatly from patient to patient
Identification of patients who are more likely to respond to paclitaxel would help to customize treatment of breast cancer and avoid unnecessary treatment with chemotherapy of patients who are unlikely to respond to treatment
Materials and Methods
Needle samples from 75 patients with primary breast cancer (>3 cm) were taken prior to treatment
Patients were divided into 5 groups depending on their response to neoadjuvant paclitaxel.
Group 1: extremely resistant (n=6)
Group 2: resistant (n=5)
Group 3: moderate responder (n=11)
Group 4: responder (n=5)
Group 5: high responder (n=7)
RNA was extracted from the needle samples and profiled on cDNA microarrays of 23,000 human transcripts
RNA expression was validated using semi-quantitative RT-PCR
Differentially expressed genes between the extremely resistant (Group 1) and high responder (Group 5) groups were selected by Mann-Whittney U-test (p<0.05)
A high score predictive set of gene was selected from these genes using a machine-learning method comparing the non-responders (Groups 1,2) and the responders (Groups 3,4,5)
The predictive set of genes was tested using leave-one-out cross-validation on the original research set of patients
Single nucleotide polymorphism (SNP) analysis was performed to identify genes that predict for side effects from treatment
Results
Of the 75 patients initially included, 24 patients were excluded due to lack of sufficient material to perform the microarray analysis
An additional 17 patients were removed from the research set to form a validation set, leaving 34 total patients from which the gene set was selected
Overall, clinical response rate to treatment was 74% with a pathologic complete response rate of 3%
Grade III/IV toxicity to chemotherapy treatment was seen in 7% of patients
66 differentially expressed genes were selected that discriminated between Groups 1 and 5
A predictive set of 7 genes was selected from these genes using the machine-learning repeats method
All 33/34 patients (97%) were correctly classified on cross-validation analysis
2716 SNPs from 298 genes on 54 patients were analyzed for prediction of side effects, and 2 genes (CYP2C8 and BUB1b) were found to be closely related to granulocytopenia
Author's Conclusions
The expression of 7 genes can predict response to paclitaxel chemotherapy with an accuracy of 97%
Two genes identified by SNP analysis can predict for granulocytopenia with treatment
Clinical/Scientific Implications
This study describes a gene expression profile that may predict for response to treatment with paclitaxel of breast cancer patients. Compared to similar studies using microarrays to screen large numbers of genes to find a predictive gene set, this study has the advantage of holding a high predicitive value using a small number of genes. Like many studies using microarray technology, this study suffers from a lack of validation of the gene set against an independent set of patients. It is not surprising that testing the gene set against the group of patients from which that set is derived would accurately group those patients. An independent set of 17 patients have been removed from the original patient set in this study; unfortunately, the analysis of these patients was not yet completed at the time of this report. Despite these shortcomings, this study holds interesting promise in predicting an individual's response to a paclitaxel therapy. In theory, studies such as this may one day lead to the development of clinical test that would help tailor therapy to individual patients. Currently, the clinical applicability of gene profiling studies is extremely limited; however, the future potential for these studies is high.
Given that the SEC filings that aries refers to are dated a month after the posts you list, I think with hindsight you might agree that you are perhaps mistaken in this instance.
ifida, it's a shame there are no notes to go with it. I found a Shriver PowerPoint presentation and (somewhere else completely) a transcript of the presentation that he gave. Put the two together and it's quite different from just looking at the slides.
aries4747 is the first to my recollection to post the details of the PRE 14C (filed on 6 August) and SC 13D (filed on 8 August).
Forensic Bioinformatics 3rd Annual Conference
August 20 - 22, 2004
http://www.bioforensics.com/conference04/conference04.html
Saturday, August 21st
10:00 - 10:30 : Racial identification and future applications of SNPs (Dr. Theodore Kessis, Applied DNA Resources)
http://www.bioforensics.com/conference04/Racial_Identification/index.html
Zach Gaskin presentation
Z. Gaskin. (2004). ``DNA Witness: A presumptive DNA test for bio-geographical ancestory.'' Cambridge Healthtech Institute's 6th Biannual Conference: DNA Forensics - Enabling Investigative Examination. McLean, VA. June 24-25, 2004.
http://www.bioforensics.com/conference04/Racial_Identification/DNA_Witness.pdf
Human identification project update:
http://diagnosticscrc.org/CDxAdmin/AnnRep2003.pdf
The short-term objectives of this project are to identify SNPs responsible for characteristics such as pigmentation by comparison of DNA sequences in population samples of differing phenotypes. This will be achieved by a combination of database mining and comparative genomics to investigate candidate genes for SNPs associated with particular phenotypes (eg hair colour). This will constitute a patentable ID profile with enormous value to the forensics industry where such information would greatly simplify and better direct forensic investigations.
MILESTONES FOR 2002-2003
Recruitment of volunteers to establish DNA database for human identification
• Volunteers have been recruited by public media advertising and QUT staff and students.
Ongoing collection of samples from study subjects
• Approximately 250 venipuncture blood samples have been collected from volunteers to date.
Identification of further pigmentation gene SNPs by database mining
• Approximately ten additional pigmentation genes have been identified by database mining.
Identification of candidate pigmentation gene SNPs and analyse in the population samples
• Approximately 250 SNPs (100 coding, 100 5’- and 50 3’- untranslated) have been identified in 25 genes by database mining.
• Twelve SNPs have been analysed in population samples.
Identification of candidate genes for facial morphology
• Approximately 20 genes have been identified as potential genes involved in facial morphology based on animal models.
PLANNED ACTIVITIES
Milestones for 2003-2004
• Identification of pigmentation, height and facial morphology gene SNPs by database mining.
• Identification candidate pigmentation, height and facial morphology gene SNPs.
• Analysis of SNPs in the population samples.
• Integrate these activities with Project 6 in a combined ‘Genome Diagnostics’ project.
Milestones for the period after 30 June 2004
• Analysis of subset of population samples using SNP chip technology.
• Analysis of the SNP chip data.
• Screening of SNPs significantly associated with phenotype in a larger population group.
Did anybody see this by an Australian anti-aging researcher from July 2004?
http://www.eternalhealth.org/doctor/michael_elstein.htm
http://www.eternalhealth.org/archives/whats_new/june%201sta%202004.htm
Sarcoidosis, emphysema, SARS, West Nile virus and aging update
Two weeks ago one of the questions concerned treatment for sarcoidosis and I indicated that treatment of a bacterium thought to underly this disease might lead to significant improvements. What I have since discovered via communication with an extremely brilliant physician and research scientist Dr David Moskowitz whose website is located at www.genomedics.com is that angiotensin 2, a substance manufactured in the lung might be responsible for the promotion of sarcoidosis, emphysema, SARS and even ageing. Now angiotensin 2 is the chemical that is also responsible for raising blood pressure and we have medications commonly known as ACE inhibitors and angiotensin receptor blockers or ARBs for modulating angiotensin 2 which reduces blood pressure. According to ground-breaking research conducted by Dr Moskowitz and his colleagues angiotensin 2 might also instigate the promulgation of free radicals and at the same time might be responsible for the processes that drive sarcoidosis, emphysema, SARS, West Nile Virus disease and even aging. In other words medications that are commonly reserved for the treatment of high blood pressure can also be used to treat sarcoidosis, emphysema, viral illnesses such as SARS and even to prevent aging. I suggest you look at the above website to get acquainted with this exciting new research.
Dave Moskowitz is presenting a Vendor Case Study at this Disease Management Convention in September:
http://www.diseasemanagementcongress.com/dmc2004_vendorcasestudy.asp
Monday, September 20, 2004
12:30-12:50pm
Medical Genomics: Saving Healthcare Costs by Improving Patient Outcomes
Presenter: David W. Moskowitz, MD- Chairman, Chief Executive Officer, and Chief Medical Officer, GenoMed, Inc.
For centuries, people have dreamed of this moment: when science would lead directly to effective treatment and prevention of disease. With medical genomics, the knowledge of which genes cause which diseases, the moment has finally arrived. Here we show that knowing a single "master" disease gene which already has FDA-approved inhibitors could transform healthcare globally. We have already seen that kidney failure due to diabetes and hypertension can be prevented, and emphysema delayed. Three-quarters of common diseases may be amenable to this same treatment approach, including most viral diseases.
In this session, you’ll:
Understand basic medical genomics, which is already capable of delivering on its promise
Understand the economic, social, and political ramifications of effective preventive medicine
Understand what Next Generation DM(tm) [Disease Management] looks like
OT I have been asked to post in the absence of a particular individual, and will do so while this individual is not active on this board.
Robert, thanks. A citation of one of our articles in a Nature Genetics article together with specific acknowledgement of the use of DNAP data. Does it get any better than this?
Robert, one of the most interesting connections in the Affymetrix work is of course the following:
http://www.ingenta.com/isis/searching/Expand/ingenta?pub=infobike://hsp/hg/2004/00000001/00000004/ar...
The genomic distribution of population substructure in four populations using 8,525 autosomal SNPs
Human Genomics May 2004, vol. 1, no. 4, pp. 274-286(13)
Shriver M.D.[1]; Kennedy G.C.[2]; Parra E.J.[3]; Lawson H.A.[1]; Sonpar V.[1]; Huang J.[2]; Akey J.M.[4]; Jones K.W.[2]
[1] Penn State University, University Park, Pennsylvania, USA [2] Affymetrix, Inc., Santa Clara, California, USA [3] University of Toronto at Mississauga, Mississauga, Canada [4] Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Abstract:
Understanding the nature of evolutionary relationships among persons and populations is important for the efficient application of genome science to biomedical research. We have analysed 8,525 autosomal single nucleotide polymorphisms (SNPs) in 84 individuals from four populations: African-American, European-American, Chinese and Japanese. Individual relationships were reconstructed using the allele sharing distance and the neighbour-joining tree making method. Trees show clear clustering according to population, with the root branching from the African-American clade. The African-American cluster is much less star-like than European-American and East Asian clusters, primarily because of admixture. Furthermore, on the East Asian branch, all ten Chinese individuals cluster together and all ten Japanese individuals cluster together. Using positional information, we demonstrate strong correlations between inter-marker distance and both locus-specific FST (the proportion of total variation due to differentiation) levels and branch lengths. Chromosomal maps of the distribution of locus-specific branch lengths were constructed by combining these data with other published SNP markers (total of 33,704 SNPs). These maps clearly illustrate a non-uniform distribution of human genetic substructure, an instructional and useful paradigm for education and research.
Keywords: population genomics; population genetics; microarray; genotyping; evolution; admixture
Document Type: Research article ISSN: 1473-9542
SICI (online): 1473-9542(20040501)1:4L.274;1-
Matsuzaki H, Loi H, Dong S, Tsai YY, Fang J, Law J, Di X, Liu WM, Yang G, Liu G, Huang J, Kennedy GC, Ryder TB, Marcus GA, Walsh PS, Shriver MD, Puck JM, Jones KW, Mei R.
Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array.
Genome Res. 2004 Mar;14(3):414-25.
Affymetrix, Inc., Santa Clara, California 95051, USA.
The analysis of single nucleotide polymorphisms (SNPs) is increasingly utilized to investigate the genetic causes of complex human diseases. Here we present a high-throughput genotyping platform that uses a one-primer assay to genotype over 10,000 SNPs per individual on a single oligonucleotide array. This approach uses restriction digestion to fractionate the genome, followed by amplification of a specific fractionated subset of the genome. The resulting reduction in genome complexity enables allele-specific hybridization to the array. The selection of SNPs was primarily determined by computer-predicted lengths of restriction fragments containing the SNPs, and was further driven by strict empirical measurements of accuracy, reproducibility, and average call rate, which we estimate to be >99.5%, >99.9%, and>95%, respectively [corrected]. With average heterozygosity of 0.38 and genome scan resolution of 0.31 cM, the SNP array is a viable alternative to panels of microsatellites (STRs). As a demonstration of the utility of the genotyping platform in whole-genome scans, we have replicated and refined a linkage region on chromosome 2p for chronic mucocutaneous candidiasis and thyroid disease, previously identified using a panel of microsatellite (STR) markers.
http://egweb.bcgsc.ca/journal_club/2003_2004/pdfs/journal_club_040322.pdf
Here's a little bit more about Lonnie Bookbinder:
http://leg.state.mt.us/content/committees/interim/2003_2004/econ_affairs/Economic_development_postin....
Hello All:
Recently Russ (Fletcher) and others sent or told us about other states and their role in facilitating economic development. Below is a great example of State (Indiana) government, companies and universities working together to 'seed' or fund the life sciences and product commercialization.
This accomplishment is the result of vision, leadership and focus. Montana needs to do something similar. This is not that difficult to do, as we have seen many states figure this out and step into the modern period of economic development. Who makes this decision in Montana?
Please share this message with them and let's engage them directly in discussion directed towards investing in Montana's future. We need a Montana Future Fund, who will lead the way?
Lonnie Bookbinder, CEO
ProteoGenesis
winbig, I'm sure that is what it is - perhaps an IT security expert in this case.
It's a bit difficult to tell what most of these are (and in whose favor they are in some cases) without the backing detail. The protective order obviously seeks to restrict one party in an unknown respect. I was more interested in the "motion to withdraw" and the subsequent order denying the motion. I would guess this is not DNAP seeking to withdraw. The other intriguing one was the "order appointing Special Master". I'm not sure if this relates to a martial arts related punishment for Dr K, is a reference to some masonic practice that the Florida Circuit Court engages in, or is something else entirely. Time will tell...
There has been a flurry of activity in the civil case against Venkateswarlu Kongdragunta. Here are the dockets so far for July and August:
7/9/2004 NOTICE - DEPOSITION
7/9/2004 MOTION TO WITHDRAW
7/15/2004 ORDER ON MOTION FOR CAMERA INSPECTION
7/28/2004 NOTICE OF HEARING
7/29/2004 OPPOSITION TO MOTION
7/29/2004 MOTION - EMERGENCY
7/29/2004 MOTION - COMPEL (ATTACHMENTS)
7/30/2004 MOTION - PROTECTIVE ORDER
8/2/2004 COURT APPEARANCE RECORD
8/2/2004 NOTICE OF CANCELLATION - HEARING
8/3/2004 NOTICE OF HEARING
8/4/2004 ORDER DENYING MOTION TO WITHDRAW
8/4/2004 ORDER APPOINTING SPECIAL MASTER
Looks as if matters are coming to a conclusion...
Nice post MONEYPIG. Now, how many categories will the test use? Eight? Sixteen? Or some other number?
DNAWitness 2.5
http://www.investorshub.com/boards/read_msg.asp?message_id=3471049
As we reach our first anniversary as a management team, I am encouraged by our progress. We improved our consumer product ANCESTRYbyDNA™ and upgraded it from a 71-marker test to a 175-marker test. We intend to continue improving the product, its accuracy and its ability to scan a broader platform of genetic heritage. Our goal is to expand our current 4 categories of inherited genetic markers to 8 and possibly 16 categories.
Here's the 8 way classification (I missed this):
http://www.newscoast.com/apps/pbcs.dll/article?AID=/20040714/BUSINESS/407140540/-1/TOPHOMES
DNAWitness 2.5 determines a person's proportional ancestry from among four major population groups around the world: Native American, East Asian, Indo-European or sub-Saharan African heritage. It also can distinguish whether a person's European descent is primarily of continental European, Middle Eastern or Indo-Pakistani origin.
Someone's East Asian ancestry can be further specified as Northern, Central or Southeast Asian.
So, that gives:
Native American (1)
East Asian - subdivided into Northern (2), Central (3), Southeast Asian (4)
Indo-European - subdivided into continental European (5), Middle Eastern (6), Indo-Pakistani (7)
Sub-Saharan African (8)
I’ve mentioned Joanna Mountain before:
http://www.investorshub.com/boards/read_msg.asp?message_id=1379293
Joanna is one of the people mentioned here on Mark Shriver’s PSU website under the category "Collaborators, Friends, and other important people":
http://anthro.psu.edu/biolab/ports/index.html
Now, how about this grant:
Grant Number: 5P01GM028428-230013
PI Name: MOUNTAIN, JOANNA L.
Project Title: PATTERNS OF GENETIC VARIATION
Abstract: Haplotypes generated for linked genetic markers, particularly markers with differing mutation rates, provide a potentially rich source of information regarding the details of human history. The first major goal of this Subproject is to develop between 25 and 50 new haplotyping systems, each consisting of a single short tandem repeat (STR), or microsatellite, polymorphism linked to one or more single nucleotide polymorphisms (SNPs). The second major goal is to determine haplotypes for these systems for approximately 1000 individuals from a geographically and linguistically diverse set of human populations. From these 50,000-100,000 haplotypes (two per individual per system) we will summarize patterns of variation in terms of genetic diversity, population heterogeneity, and linkage disequilibrium. We will then infer the extent to which population size changes (bottlenecks, expansions, contractions), population admixture, and isolation among populations have played roles in human evolutionary history. Through the development of new haplotyping systems and the inference of additional details of human history, this project will provide valuable resources and information to researchers in both medicine and anthropology.
Thesaurus Terms:
biochemical evolution, gene expression, gene mutation, genetic polymorphism, haploidy, human population genetics gene frequency, linkage disequilibrium, natural selection, nucleic acid repetitive sequence high performance liquid chromatography, human genetic material tag, human tissue
Institution: STANFORD UNIVERSITY STANFORD, CA 94305
Fiscal Year: 2004
ICD: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
The details of this research can be found here:
http://www.stanford.edu/group/mountainlab/research/snpstr/abstract.html